The Food and Drug Administration on Monday expanded approval for Bristol-Myers Squibb's cancer drug Yervoy to treat pediatric populations.
Yervoy is an intravenous injection first approved in 2011 to treat adults with metastatic melanoma. The drug may now be used to treat patients 12 years and older with unresectable or metastatic melanoma.
The approval marks Bristol Myers' first pediatric indication for an immunotherapy drug.
More articles on supply chain:
Supply chain leaders worried about potential market entry of Amazon
Drug prices will jump nearly 8% for health systems in 2018: 3 report findings
10 most popular prescription drugs for 2017